118 related articles for article (PubMed ID: 38658032)
21. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
22. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
Mossoba ME; Walia JS; Rasaiah VI; Buxhoeveden N; Head R; Ying C; Foley JE; Bramson JL; Fowler DH; Medin JA
Mol Ther; 2008 Mar; 16(3):607-17. PubMed ID: 18180774
[TBL] [Abstract][Full Text] [Related]
23. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses.
Santos PM; Adamik J; Howes TR; Du S; Vujanovic L; Warren S; Gambotto A; Kirkwood JM; Butterfield LH
J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32369107
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
25. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
26. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
27. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic vaccination targeting CD40 and TLR3 controls melanoma growth through existing intratumoral CD8 T cells without new T cell infiltration.
Stevens AD; Bullock TNJ
Cancer Immunol Immunother; 2021 Aug; 70(8):2139-2150. PubMed ID: 33452626
[TBL] [Abstract][Full Text] [Related]
29. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
30. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
[TBL] [Abstract][Full Text] [Related]
31. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
32. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
[TBL] [Abstract][Full Text] [Related]
33. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
34. IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies.
Audsley KM; Wagner T; Ta C; Newnes HV; Buzzai AC; Barnes SA; Wylie B; Armitage J; Kaisho T; Bosco A; McDonnell A; Cruickshank M; Fear VS; Foley B; Waithman J
Front Immunol; 2021; 12():735133. PubMed ID: 34552594
[TBL] [Abstract][Full Text] [Related]
35. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
36. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
[TBL] [Abstract][Full Text] [Related]
38. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
39. Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses.
Rowe HM; Lopes L; Brown N; Efklidou S; Smallie T; Karrar S; Kaye PM; Collins MK
J Virol; 2009 Feb; 83(4):1555-62. PubMed ID: 19036811
[TBL] [Abstract][Full Text] [Related]
40. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]